<DOC>
	<DOCNO>NCT00305019</DOCNO>
	<brief_summary>The purpose study determine antiviral effect safety clevudine 30 mg day ( QD ) 50 mg QD patient infect hepatitis B virus ( HBV ) .</brief_summary>
	<brief_title>Safety Antiviral Activity Clevudine Patients Infected With Hepatitis B Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patient 18 60 year age , inclusive 2 . Patient HBV DNA positive DNA level screen 3 x 10^6 copies/mL . 3 . Patient document hepatitis B surface antigen ( HBsAg ) positive &gt; 6 month . Patient HBeAg positive antiHBe negative . Evidence HBsAg ( + ) previous 6 month may include follow : documentation HBsAg ( + ) previous 6 month documentation HBsAg ( + ) previous 3 month IgM antiHBc negative screening IgM antiHBc negative IgG antiHBc positive screening 4 . Patient ALT level range 2 less 10 time upper limit normal ( x ULN ) bilirubin level &lt; 1.5 x ULN . 5 . Female patient negative serum ( HCG ) pregnancy test take within 14 day start therapy . 6 . Patient able give write informed consent prior study start comply study requirement . 7 . Patients continue meet following criterion completion Week 36 visit additional followup visit Week 40 , 44 , 48 : receive additional therapy since completion 12 week treatment LFMAU continue period 1 log10 decrease HBV DNA baseline . 1 . Patient currently receive antiviral , immunomodulatory corticosteroid therapy . 2 . Patients previously treat lamivudine , lobucavir , adefovir investigational nucleoside HBV infection . 3 . Patients previous treatment interferon end less 6 month prior screen visit . 4 . Patient history ascites , variceal hemorrhage hepatic encephalopathy . 5 . Patient coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) HIV . 6 . Patient clinical evidence cirrhosis hepatocellular carcinoma 7 . Patient pregnant breastfeeding . 8 . Patient unwilling use “ effective ” method contraception study 30 day use study drug cease . For male , condom use . Females must surgically sterile ( via hysterectomy bilateral tubal ligation ) , postmenopausal use least medically acceptable barrier method contraception ( i.e. , intrauterine device [ IUD ] , barrier method spermicide abstinence ) 9 . Patient clinically relevant history abuse alcohol drug . 10 . Patient significant gastrointestinal , renal , hepatic ( decompensated ) , bronchopulmonary , neurological , cardiovascular , oncologic allergic disease . 11 . Patient creatinine clearance le 60 mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ] Patients found tyrosine , methionine , aspartate , aspartate ( YMDD ) HBV DNA polymerase mutation enrollment exclude efficacy evaluation include safety evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>